HIMS logo

Hims & Hers Health Inc. Class A (HIMS)

$17.55

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on HIMS

Market cap

$4.11B

EPS

-0.83

P/E ratio

--

Price to sales

2.8

Dividend yield

--

Beta

2.528844

Price on HIMS

Previous close

$18.56

Today's open

$18.38

Day's range

$17.14 - $18.70

52 week range

$13.74 - $40.99

Profile about HIMS

CEO

Andrew Dudum

Employees

2442

Headquarters

San Francisco, CA

Exchange

New York Stock Exchange

Shares outstanding

234412422

Issue type

Common Stock

HIMS industries and sectors

Consumer Staples

Consumer Products - Household & Personal

News on HIMS

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

Hims & Hers Health said it will now offer five new peptides and longevity treatments compounded in the U.S. as part of the initial rollout of its Peptides+ platform. The telehealth company will now offer compounded formulations of sermorelin, glutathione, and NAD+, as well as vitamin B-12 and L-carnitine, none of which are approved by the FDA.

news source

CNBC • 4 hours ago

news preview

Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC.

news source

Business Wire • 4 hours ago

news preview

Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?

Hims & Hers Health grew its revenue by 49% last quarter. The company incurred a loss, however, as its gross margins deteriorated.

news source

The Motley Fool • Nov 16, 2026

news preview

Hims & Hers: Further Expanding Internationally

Hims & Hers Health is a Strong Buy: my $23.8 implied share price offers roughly 20% upside while targeting a 15% annual return. International expansion is the principal growth driver, with revenue guidance raised to at least $650 million in 2026 and $1 billion expected in 2027. HIMS faces near-term margin pressure and subscriber headwinds; Q3 gross margin fell to 57%, while subscribers declined by 103,000 sequentially.

news source

Seeking Alpha • Nov 16, 2026

news preview

Why Is Hims Stock Crashing, and is it a Buying Opportunity?

Revenue is increasing, but so are its operating expenses.

news source

The Motley Fool • Nov 14, 2026

news preview

Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?

Hims & Hers stock is facing margin pressure as it increases sales of branded weight-loss drugs and expands internationally. The company has a big opportunity in the peptide market.

news source

The Motley Fool • Nov 13, 2026

news preview

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

news source

Zacks Investment Research • Nov 13, 2026

news preview

HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs

Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform.

news source

Zacks Investment Research • Nov 13, 2026

news preview

Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off

Even a nearly 9% rebound on Wednesday, Nov. 11, couldn't undo a punishing start to the week for Hims & Hers Health NYSE: HIMS. Shares had already plunged nearly 12% ahead of Monday evening's Q3 earnings report, and disappointing results—a double miss—sent the stock tumbling another 16.6% on Tuesday.

news source

MarketBeat • Nov 12, 2026

news preview

Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board

Hims & Hers Health Inc. (NYSE:HIMS) had a busy week that included third-quarter results that missed estimates, a new board member in Andrew Huberman and a round of analyst price target changes.

news source

Benzinga • Nov 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Hims & Hers Health Inc. Class A

Open an M1 investment account to buy and sell Hims & Hers Health Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in HIMS on M1